Email
Print
Biomarker-Based Diagnostic Panel Market – By Type (Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers), By Application (Oncology, Cardiology, Nephrology, and Others), By End Use (Hospitals, Research Institutes, Diagnostic Labs), By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030
Biomarker-Based Diagnostic Panel Market Overview:
Biomarker-Based Diagnostic Panel Market size is estimated to reach $30 billion by 2030, growing at a CAGR of 12% during the forecast period 2024-2030. The market for Biomarker-Based Diagnostic Panels is primarily driven by several key factors contributing to its growth. These include the growing importance of companion diagnostics, the increasing prevalence of personalized medicine approaches, the rise in investment in biomarker research activities, elevated demand for non-invasive diagnostic tests, and technological advancements in disease diagnosis. In April 2023, Oxford Cancer Biomarkers Ltd (OCB) concluded a successful funding round led by Plutus Investment Group LLP, highlighting its leadership in AI-driven precision cancer diagnostics.
The increasing demand for Biomarker-Based Diagnostic Panels is primarily attributed to the heightened emphasis on personalized medicine approaches, where biomarkers play a crucial role in tailoring diagnostics and treatments to individual patient profiles. This demand is further fueled by the growing importance of companion diagnostics, facilitating the identification of optimal therapeutic strategies based on specific biomarker profiles. These factors positively influence the Biomarker-Based Diagnostic Panel industry outlook during the forecast period.
Biomarker-Based Diagnostic Panel Market - Report Coverage:
The “Biomarker-Based Diagnostic Panel Market Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Biomarker-Based Diagnostic Panel Market.
COVID-19 / Ukraine Crisis - Impact Analysis:
● The Biomarker-Based Diagnostic Panels industry has been significantly affected by the COVID-19 pandemic. Supply chain disruptions, workforce challenges, and decreased healthcare access have hindered production and adoption. However, the industry also witnessed increased focus on diagnostic biomarkers for COVID-19 and related complications, presenting opportunities for innovation and market expansion.
● The Russia-Ukraine war has had a notable impact on the Biomarker-Based Diagnostic Panels industry, introducing disruptions in the global supply chain for critical components and materials. The conflict has led to uncertainties in trade, causing challenges in the production and distribution of diagnostic panels. Additionally, geopolitical tensions have influenced investor confidence and strategic decision-making, potentially affecting research and development initiatives in the field.
Key Takeaways:
● Asia-Pacific to Register Highest Growth
Geographically, in the global Biomarker-Based Diagnostic Panel Market, Asia-Pacific is analyzed to grow with the highest CAGR of 13.2% during the forecast period 2024-2030. In the dynamic landscape of the Biomarker-Based Diagnostic Panel industry, Asia Pacific stands out as the fastest-growing region, poised to play a pivotal role in shaping the sector's future. The region's robust growth can be attributed to a confluence of factors, including a rising awareness of the importance of early disease detection and an increasing focus on personalized medicine. The demand for diagnostic biomarkers is witnessing an unprecedented surge, fueled by advancements in healthcare infrastructure and a proactive approach to healthcare in countries like China and India. India Brand Equity Foundation, In July 2022, the World Bank approved a US$ 1 billion loan towards India's Pradhan Mantri-Ayushman Bharat Health Infrastructure Mission. Additionally, the burgeoning middle-class population in the region, with an increasing disposable income, is driving the adoption of cutting-edge diagnostic technologies.
● Safety Biomarkers Segment to Register the Fastest Growth
In the Biomarker-Based Diagnostic Panel Market analysis, the Construction segment is estimated to grow with the highest CAGR of 12.9% during the forecast period 2024-2030. In the dynamic landscape of the Biomarker-Based Diagnostic Panel industry, Safety Biomarkers emerging as the fastest-growing segment, charting unprecedented progress. These biomarkers, measured before or after exposure to medical products or environmental agents, play a pivotal role in indicating the likelihood, presence, or extent of adverse effects, thereby ensuring enhanced safety protocols in healthcare interventions. The industry's focus on establishing biomarker-based diagnostic methods has propelled Safety Biomarkers to the forefront, with a keen eye on their qualification for regulatory acceptance and utilization. As stakeholders increasingly recognize the importance of comprehensive safety assessments, the demand for biomonitoring capabilities has intensified, further propelling the prominence of Safety Biomarkers in the industry.
● Advancements in Laboratory Techniques is Propelling the Market Growth.
Advancements in laboratory techniques serve as a prominent driver for the growth of the Biomarker-Based Diagnostic Panel market. The continuous evolution of laboratory technologies, such as high-throughput screening, next-generation sequencing, and precision medicine approaches, has significantly enhanced the capabilities of biomarker discovery, validation, and implementation in diagnostics. These advancements enable researchers and clinicians to identify and analyze a myriad of biomarkers with unprecedented accuracy and efficiency, leading to the development of sophisticated diagnostic panels. The Biomarker-Based Diagnostic Panel market benefits from the synergistic relationship between advancements in laboratory techniques and the quest for precision diagnostics, driving the demand for these innovative panels in clinical settings.
● High development costs Limiting the Market Growth.
The Biomarker-Based Diagnostic Panel industry confronts a significant market challenge in the form of high development costs. The process of identifying, validating, and incorporating biomarkers into diagnostic panels demands substantial financial investments. Research and development efforts to discover novel biomarkers with high specificity and sensitivity require extensive laboratory work, clinical trials, and data analysis. Additionally, the stringent regulatory requirements and quality assurance standards imposed by health authorities contribute to elevated development costs. These financial barriers often pose challenges for smaller companies and startups looking to enter the market, limiting their ability to compete with more established players. The complexity of biomarker discovery, coupled with the need for cutting-edge technologies and specialized expertise, further amplifies the cost burden.
Biomarker-Based Diagnostic Panel Market Share (%) By Region, 2023
Key Market Players:
Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the Biomarker-Based Diagnostic Panel Market. The top 10 companies in this industry are listed below:
1. Abbott Laboratories
2. BioMerieux
3. Merck KgaA
4. Roche Diagnostics
5. Metabolomic Diagnostics
6. Almac Diagnostic Services
7. Danaher Corporation
8. Thermo Fisher Scientific
9. Randox Laboratories Ltd.
10. Qiagen
Scope of Report:
Relevant Reports:
Report Code: HCR 0182
Report Code: HCR 0194
1. Biomarker-Based Diagnostic Panel Market - Overview
1.1 Definitions and Scope
2. Biomarker-Based Diagnostic Panel Market - Executive Summary
3. Biomarker-Based Diagnostic Panel Market - Comparative Analysis
3.1 Company Benchmarking
3.2 Global Financial Analysis
3.3 Market Share Analysis
3.4 Patent Analysis
3.5 Pricing Analysis
4. Biomarker-Based Diagnostic Panel Market - Start-up Companies Scenario Premium
4.1 Key Start-up Company Analysis by
4.1.1 Investment
4.1.2 Revenue
4.1.3 Venture Capital and Funding Scenario
5. Biomarker-Based Diagnostic Panel Market – Industry Market Entry Scenario Premium Premium
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing Business Index
5.3 Case Studies of Successful Ventures
6. Biomarker-Based Diagnostic Panel Market - Forces
6.1 Market Drivers
6.2 Market Constraints/Challenges
6.3 Porters Five Force Model
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes
7. Biomarker-Based Diagnostic Panel Market – Strategic Analysis
7.1 Value Chain Analysis
7.2 Opportunities Analysis
7.3 Market Life Cycle
8. Biomarker-Based Diagnostic Panel Market Segment Analysis – By Type
8.1 Safety Biomarkers
8.2 Efficacy Biomarkers
8.3 Validation Biomarkers
9. Biomarker-Based Diagnostic Panel Market Segment Analysis – By Application
9.1 Oncology
9.2 Cardiology
9.3 Nephrology
9.4 Others
10. Biomarker-Based Diagnostic Panel Market Segment Analysis – By End Use
10.1 Hospitals
10.2 Research Institutes
10.3 Diagnostic Labs
11. Biomarker-Based Diagnostic Panel Market Segment Analysis -By Geography
11.1 North America
11.1.1 U.S.
11.1.2 Canada
11.1.3 Mexico
11.2 Europe
11.2.1 U.K.
11.2.2 Germany
11.2.3 France
11.2.4 Italy
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Asia-Pacific
11.3.1 China
11.3.2 India
11.3.3 Japan
11.3.4 South Korea
11.3.5 Australia & New Zealand
11.3.6 Rest of Asia-Pacific
11.4 South America
11.4.1 Brazil
11.4.2 Argentina
11.4.3 Chile
11.4.4 Colombia
11.4.5 Rest of South America
11.5 Rest of the World
11.5.1 Middle East
11.5.2 Africa
12. Biomarker-Based Diagnostic Panel Market - Entropy
13. Biomarker-Based Diagnostic Panel Market – Industry/Segment Competition Landscape Premium
13.1 Market Share Analysis
13.1.1 Global Market Share – Key Companies
13.1.2 Market Share by Region – Key companies
13.1.3 Market Share by Countries – Key Companies
13.2 Competition Matrix
13.3 Best Practices for Companies
14. Biomarker-Based Diagnostic Panel Market – Key Company List by Country Premium Premium
15. Biomarker-Based Diagnostic Panel Market - Company Analysis
15.1 Abbott Laboratories
15.2 BioMerieux
15.3 Merck KgaA
15.4 Roche Diagnostics
15.5 Metabolomic Diagnostics
15.6 Almac Diagnostic Services
15.7 Danaher Corporation
15.8 Thermo Fisher Scientific
15.9 Randox Laboratories Ltd.
15.10 Qiagen
"Financials to the Private Companies would be provided on best-effort basis."
Connect with our experts to get customized reports that best suit your requirements. Our
reports include global-level data, niche markets and competitive landscape.
The Biomarker-Based Diagnostic Panel Market is projected to grow at 12% CAGR during the forecast period 2024-2030.
Global Biomarker-Based Diagnostic Panel Market size is estimated to be $13.5 billion in 2023 and is projected to reach $30 billion by 2030.
The leading players in the Biomarker-Based Diagnostic Panel Market are Abbott Laboratories, BioMerieux, Merck KgaA, Roche Diagnostics, Metabolomic Diagnostics and others.
The Biomarker-Based Diagnostic Panels market is poised for significant evolution driven by several prominent trends. Firstly, the increasing emphasis on personalized medicine is anticipated to fuel the demand for biomarker-based diagnostics, allowing for tailored treatment strategies. Secondly, advancements in technology, such as the integration of artificial intelligence and machine learning, are likely to enhance the precision and efficiency of diagnostic panel analyses.
The Biomarker-Based Diagnostic Panels market is driven by the increasing demand for personalized medicine, emphasizing the crucial role of biomarkers in tailoring treatments. Growing importance of companion diagnostics further fuels market growth by aiding in therapeutic strategy identification based on biomarker profiles. Technological advancements in disease diagnosis contribute significantly, enhancing the appeal of Biomarker-Based Diagnostic Panels. Opportunities lie in the expansion of personalized medicine approaches, leveraging biomarkers for targeted interventions and optimized patient outcomes.